Jefferies initiated coverage on ANI Pharma with a new price target
$ANIP
Biotechnology: Pharmaceutical Preparations
Health Care
Jefferies initiated coverage of ANI Pharma with a rating of Buy and set a new price target of $80.00
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/10/2025 | $84.00 | Buy | H.C. Wainwright |
| 3/14/2025 | $80.00 | Buy | Jefferies |
| 3/12/2025 | $85.00 | Overweight | Analyst |
| 12/11/2024 | $80.00 | Outperform | Leerink Partners |
| 10/11/2024 | $68.00 | Overweight | Piper Sandler |
| 3/15/2024 | $80.00 | Overweight | CapitalOne |
| 8/22/2023 | $60.00 → $73.00 | Buy | H.C. Wainwright |
| 3/1/2023 | $55.00 | Buy | Guggenheim |
Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the aflibercept arm Study Enrolled Treatment-Naïve, or Almost Naïve, Patients with DME Results presented by Michael A. Singer, M.D. in a paper-on-demand presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting Conference call scheduled for today at 8:30 am ET PRINCETON, N.J., July 23, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced results from the NEW DAY clinical trial of ILUVIEN® (fluocinolone acetonide intravitreal implant), 0.19 mg (ILUVIEN) for use in patients with diabetic macula
PRINCETON, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, will host 1x1 meetings at the Leerink Partners Therapeutics Forum: I&I and Metabolism on Tuesday, July 8, 2025, in Boston, MA. About ANI Pharmaceuticals, Inc. ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) is a diversified biopharmaceutical company committed to its mission of "Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets n
PRINCETON, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced new preclinical data on the use of Purified Cortrophin Gel (repository corticotropin injection USP) (Cortrophin Gel) in a mouse model of murine collagen-induced inflammatory arthritis. "In a preclinical model of murine collagen-induced arthritis, repository corticotrophin injection attenuated joint swelling in mice, and decreased inflammatory cytokine response without causing additional bone turnover, as compared to controls," said Mary Pao, MD, PhD, Chief Medical Officer of Rare Disease at ANI. "These data further expand our understanding of Cortrophin Gel's mec
8-K - ANI PHARMACEUTICALS INC (0001023024) (Filer)
8-K - ANI PHARMACEUTICALS INC (0001023024) (Filer)
S-8 - ANI PHARMACEUTICALS INC (0001023024) (Filer)
4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
H.C. Wainwright initiated coverage of ANI Pharma with a rating of Buy and set a new price target of $84.00
Jefferies initiated coverage of ANI Pharma with a rating of Buy and set a new price target of $80.00
Analyst initiated coverage of ANI Pharma with a rating of Overweight and set a new price target of $85.00
Submission status for ANI PHARMS INC's drug HYDROCODONE BITARTRATE AND IBUPROFEN (SUPPL-6) with active ingredient HYDROCODONE BITARTRATE; IBUPROFEN has changed to 'Approval' on 03/04/2021. Application Category: ANDA, Application Number: 077454, Application Classification: Labeling
Submission status for ANI PHARMS INC's drug OXYCODONE AND ASPIRIN (SUPPL-30) with active ingredient ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE has changed to 'Approval' on 03/04/2021. Application Category: ANDA, Application Number: 040255, Application Classification: Labeling
Submission status for ANI PHARMS INC's drug EZETIMIBE AND SIMVASTATIN (SUPPL-10) with active ingredient EZETIMIBE; SIMVASTATIN has changed to 'Approval' on 02/23/2021. Application Category: ANDA, Application Number: 201890, Application Classification: Labeling
Long time industry leader, Chairman of the Board Patrick Walsh replaces CEO Bill Humphries DURHAM, N.C., Jan. 13, 2025 /PRNewswire/ -- Alcami Corporation ("Alcami"), a leading contract development and manufacturing organization (CDMO), today announced the resignation of Bill Humphries. Alcami's Board Chair and former Chief Executive Officer Patrick Walsh will serve as Interim CEO, ensuring the continuation of smooth operations and a strong client-centric approach from a proven industry veteran. "On behalf of the Board, I'd like to express gratitude to Bill for his leadership
-- Mr. Leonard is an accomplished leader with 35 years of pharmaceuticals and healthcare experience -- Mr. Leonard has significant expertise in pharmacy benefits management, health insurance, and specialty and retail pharmacy -- BAUDETTE, Minn., Aug. 23, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced the addition of Matthew J. Leonard, R.Ph. to its Board of Directors. Mr. Leonard brings more than 35 years of experience as an accomplished leader and innovator within the pharmaceutical industry. This appointment is effective immediately. "We are delighted to add Matthew (Matt) Leonard to our Board of Directors. With his deep leadershi
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) ("ANI" or the "Company") today announced that Krista L. Davis will join the Company as Chief Human Resources Officer, effective September 12. Ms. Davis brings to the Company over 20 years of executive leadership experience in human resources, talent management, and organizational development. "Ms. Davis is an important addition to our leadership team and will bring strategic and innovative thought leadership to our priority people and organizational issues. Krista has a long track record of driving organizational effectiveness and delivering results across industries and cultures, most recently with Novartis, where she led global human resources for
Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the aflibercept arm Study Enrolled Treatment-Naïve, or Almost Naïve, Patients with DME Results presented by Michael A. Singer, M.D. in a paper-on-demand presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting Conference call scheduled for today at 8:30 am ET PRINCETON, N.J., July 23, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced results from the NEW DAY clinical trial of ILUVIEN® (fluocinolone acetonide intravitreal implant), 0.19 mg (ILUVIEN) for use in patients with diabetic macula
Generated record quarterly net revenues of $197.1 million, representing year-over-year growth of 43.4%Total Rare Disease quarterly net revenues of $69.0 million, which includes: Purified Cortrophin® Gel net revenues of $52.9 million, an increase of 43.1% year-over-year, andILUVIEN® and YUTIQ® net revenues of $16.1 million Record Generics net revenues of $98.7 million, an increase of 40.5% year-over-yearDelivered record quarterly adjusted non-GAAP EBITDA of $50.7 million, an increase of 34.9% year-over-yearDiluted GAAP income per share of $0.69 and record adjusted non-GAAP diluted earnings per share of $1.70Increased 2025 guidance with expected net revenues of $768.0 million to $793.0 million
PRINCETON, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that the Company will release its first quarter 2025 financial results on Friday, May 9, 2025, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease, will host a conference call to discuss the results as follows: DateFriday, May 9, 2025 Time8:00 a.m. ET Toll free (U.S.)800-225-9448 Conference ID4921902 Webcast (live and replay) www.anipharmaceuticals.com, under the "Investors" section A re
SC 13G/A - ANI PHARMACEUTICALS INC (0001023024) (Subject)
SC 13D/A - ANI PHARMACEUTICALS INC (0001023024) (Subject)
SC 13G - ANI PHARMACEUTICALS INC (0001023024) (Subject)